REMS Redesign: FDA's Opening Statement to Stakeholders
This article was originally published in RPM Report
Center for Drug Evaluation & Research Director Janet Woodcock kicked off FDA’s two day feedback meeting on the REMS July 27 with a construction analogy: FDA is still in the process of building a new house, but it is clear that there needs to be a redesign. Here are her opening remarks, from the official transcript of the meeting.
You may also be interested in...
Here are profiles of the newly appointed members of FDA's Drug Safety & Risk Management Advisory Committee.
FDA’s new post-marketing risk management authorities are receiving much more public attention in the context of the Avandia decision…but use of the REMS is actually declining. As FDAAA turns 3, it is clear that REMS are going through some growing pains. The new tools will be refined—but they are definitely here to stay.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.